| Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients (NCT03047772) | Yuejin Yang | 2018-03-06 |
| Randomized Comparison of Radiological Exposure With TRIPTable® in Patients With Acute Coronary Syndromes (NCT02200783) | Marilia Medicine School | 2014-07-01 |
| Orsiro™ Drug Eluting Stent in Routine Clinical Practice (NCT02039739) | Seung-Jung Park | 2014-06-01 |
| Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions (NCT01241903) | Susan Smyth | 2011-06-01 |
| To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study (NCT00870038) | Ospedale della Misericordia | 2010-12-01 |
| Strategies of Revascularization in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Disease (NCT01179126) | Complexo Hospitalario Universitario de A Coruña | 2010-09-01 |
| Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease (NCT01004575) | Terumo Europe N.V. | 2009-10-01 |
| Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY) (NCT01174433) | University of Padova | 2009-09-01 |
| Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention (NCT00938522) | Samsung Medical Center | 2009-07-01 |
| Left Versus Right Transradial Approach for Percutaneous Coronary Procedures (NCT00821106) | Policlinico Casilino ASL RMB | 2009-01-01 |
| Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction (NCT00979758) | Chinese Academy of Medical Sciences, Fuwai Hospital | 2009-01-01 |
| European Multicenter, Randomized, Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent (NCT00637104) | International Biomedical Systems S.p.A. | 2008-07-01 |
| Plug Arterial Closure System (PACS, 7F) (NCT00533156) | Cordis US Corp. | 2007-07-01 |
| Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention (NCT00610870) | Samsung Medical Center | 2007-07-01 |
| ECLIPSE Feasibility Trial (Ensure's Vascular Closure Device Speeds Hemostasis Trial) EU (NCT00574691) | Cordis US Corp. | 2007-06-01 |
| Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device (NCT00345631) | Cordis US Corp. | 2007-02-01 |
| Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3) (NCT00390832) | Deutsches Herzzentrum Muenchen | 2006-12-01 |
| Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial (NCT00500279) | Seoul National University Hospital | 2006-11-01 |
| Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST) (NCT00390585) | Deutsches Herzzentrum Muenchen | 2006-07-01 |
| Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance (NCT00398463) | Università degli Studi di Ferrara | 2006-05-01 |
| The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention (NCT00133731) | Sanofi | 2004-09-01 |
| Arterial Access for Coronary Intervention in Myocardial Infarction (NCT00356044) | Hospital Juan Canalejo | 2004-05-01 |
| A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab (NCT00271401) | Centocor, Inc. | 1996-07-01 |
| A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention. (NCT00269880) | Centocor, Inc. | 1995-02-01 |
| A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty (NCT00269906) | Centocor, Inc. | 1993-05-01 |
| A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty (NCT00269893) | Centocor, Inc. | 1991-11-01 |